Abstract:Abstract Introduction: In up to 10% of individuals newly diagnosed with type 2 diabetes (T2DM), diabetes is secondary to pancreatic disease, of which 10% is pancreatic cancer-related. Individuals over the age of 50 yr with new-onset diabetes are considered to be the highest risk group for pancreatic cancer (PDAC), with diabetes presenting as a paraneoplastic symptom and occurring, on average, 13 months prior to PDAC being identified. Screening in this population could facilitate earlier cancer detection, however, there is currently no test to distinguish PDAC-related diabetes (PDAC-DM; a form of type 3c diabetes) from T2DM. The aim of our study was to develop protein biomarkers capable of identifying T3cDM from T2DM to facilitate the identification of a PDAC enriched population suitable for screening. Methods: Mass spectrometry (SWATH)- and aptamer-based proteomics workflows were employed for the analysis of 210 plasma samples, comprising seven case and control groups, stratified according to diabetes status. Groups included PDAC with/without diabetes, chronic pancreatitis with/without diabetes, new-onset diabetes (<3 yr post-diagnosis) and long-standing diabetes (>3 yr post-diagnosis). Raw SWATH data was processed using a publicly available in-silico peptide library (generated by DIA-NN), with filtering for plasma proteins. Data was split into training and test sets prior to analysis and a T3cDM group was generated by combining PDAC- and chronic pancreatitis-related diabetes sample data. Linear models were created to identify proteins that were differentially expressed in multiple comparisons. Three main comparisons of interest were proteins differentially expressed between 1) T3cDM and new-onset diabetes 2) PDAC and new-onset diabetes and 3) long-standing diabetes and new-onset diabetes. From the differentially expressed proteins a classifier was trained for the distinction of T3cDM from T2DM (allowing identification of individuals whose diabetes was secondary to underlying pancreatic disease). An ensemble of models was created using a bootstrapping approach, taking forward candidate biomarkers appearing in 90% of runs for the creation of a composite biomarker. Results: Over 7500 proteins, from >6500 genes, were identified per sample. Our linear models identified distinct T3cDM (28 and 105 differentially expressed proteins from SWATH- and aptamer-platforms, respectively) and PDAC signals (72 and 102 differentially expressed proteins from SWATH- and aptamer-based platforms, respectively). These had minimal overlap with the long-standing diabetes comparison. Conclusion: We have undertaken the deepest reported interrogation of the PDAC plasma proteome to-date. The robustness of our approach is supported by the identification of both novel and existing biomarkers of PDAC. Further work is underway to interrogate the molecular pathways contributing to the pathophysiology of diabetes in PDAC. This knowledge will support the development of new biomarkers for earlier detection and will inform future treatment strategies for early disease. Citation Format: Lucy Oldfield, Emily Johnson, Eva Caamaño Gutiérrez, Martyn Stott, William Greenhalf, Christopher Halloran, Eithne Costello. Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr PR02.

Identification of Proteins Implicated in the Development of Pancreatic Cancer-Associated Diabetes Mellitus by Itraq-Based Quantitative Proteomics.

Identification of IFN-Induced Transmembrane Protein 1 with Prognostic Value in Pancreatic Cancer Using Network Module-Based Analysis.

Analysis of Protein Expression Changes in Patients with Prediabetes Using Proteomics Approaches.

Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients

Associations of Diabetes, Circulating Protein Biomarkers, and Risk of Pancreatic Cancer

Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Altered profile of serum microRNAs in pancreatic cancer associated new-onset diabetes mellitus.

Analysis of MicroRNA Signature Differentially Expressed in Pancreatic Islet Cells Treated with Pancreatic Cancer-Derived Exosomes

Construction of protein profiling models for diagnosis of pancreatic carcinoma

A Comprehensive Proteome Analysis of Peripheral Blood Mononuclear Cells (pbmcs) to Identify Candidate Biomarkers of Pancreatic Cancer

Serum metabolomics differentiating pancreatic cancer from new-onset diabetes

Elevated Expression of Exosomal Microrna-21 As a Potential Biomarker for the Early Diagnosis of Pancreatic Cancer Using a Tethered Cationic Lipoplex Nanoparticle Biochip.

Screening and Identification of Differential Expression Proteins from Pancreatic Carcinoma and Neighboring Normal Pancreatic Tissues

Abstract PR02: Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes

Differential Expressed Profile of Proteins in Normal Tissue and Pancreatic Cancer Using Proteomic Approaches

Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles.

Proteomic Analysis of Pancreatic Intraepithelial Neoplasia and Pancreatic Carcinoma in Rat Models.

Proteomics Analysis of Serum Protein Profiling in Pancreatic Cancer Patients by DIGE: Up-Regulation of Mannose-Binding Lectin 2 and Myosin Light Chain Kinase 2

Transcriptomic Analyses and Potential Therapeutic Targets of Pancreatic Cancer With Concomitant Diabetes

Proteome and secretome analysis of pancreatic cancer cells